Hepion Pharmaceuticals (HEPA) announced that Kaouthar Lbiati has been named as interim CEO, effective June 16, 2025. Dr. Lbiati is replacing John Brancaccio, who is retiring for personal reasons. Lbiati has served on Hepion’s Board of Directors since June 2022 and brings over 15 years of global leadership experience in both biotech and large pharmaceutical companies. She also serves on the board of Theralase Technologies
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HEPA:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue